2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 106

Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Abstract Number: 107

Validation of Serious Adverse Event Reporting in a Multicenter Registry
Abstract Number: 108

Development of Mental Health Guidance Statements for Pediatric Rheumatology
Abstract Number: 109

Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Abstract Number: 110

Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Abstract Number: 111

Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Abstract Number: 112

Adverse Childhood Experiences: Prevalence and Relationship to Disease in Childhood-onset Lupus
Abstract Number: 113

Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Abstract Number: 114

Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Abstract Number: 115

Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Abstract Number: 116

Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Abstract Number: 117

A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children
Abstract Number: 118

Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Abstract Number: 119

Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis
Abstract Number: 120

The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].